Skip to main content

Table 1 Patients demographics and baseline characteristics (Full Analysis Set)

From: Efficacy and safety of single injection of cross-linked sodium hyaluronate vs. three injections of high molecular weight sodium hyaluronate for osteoarthritis of the knee: a double-blind, randomized, multi-center, non-inferiority study

 

HMWHA

XLHA

P-value

(N = 146)

(N = 137)

Sex

 Male

26 (19%)

32 (22%)

0.54A

 Female

111 (81%)

114 (78%)

 

Age, years

62.38 (8.43)

61.97 (8.64)

0.68B

BMI, kg/m2

24.82 (2.65)

25.14 (2.91)

0.52C

Affected knee, patients

 Left

23 (15.75)

22 (16.06)

0.67A

 Right

26 (17.81)

30 (21.90)

 

 Bilateral

97 (66.44)

85 (62.04)

 

Duration of knee OA, years

 Left

3.08 (0.08,26)

3.83 (0.08, 22.08)

0.98C

 Right

3 (0.08, 26)

4 (0.08, 24.08)

0.19C

K-L grade, patients

 Grade I

28 (19.18)

19 (13.87)

0.36A

 Grade II

65 (44.52)

59 (43.07)

 

 Grade III

53 (36.30)

59 (43.07)

 

100 mm VAS on WBP

61.01 (13.22)

61.79 (13.76)

0.68C

WOMAC index

 Pain subscore

10.56 (3.31)

10.26 (3.05)

0.33C

 Function subscore

34.53 (11.64)

33.75 (10.53)

0.56B

 Stiffness subscore

3.97 (1.72)

3.87 (1.61)

0.72C

 Total score

49.05 (16.01)

47.88 (14.18)

0.52C

  1. BMI Body mass index, OA osteoarthritis, K-L Kellgren-Lawrence, VAS visual analogue scale, WBP weight bearing pain, WOMAC Western Ontario and McMaster Universities Osteoarthritis. Continuous variables are presented with mean (SD) except duration of knee OA, which is presented with median (min, max)
  2. A, P-value obtained from Chi-square test; B, P-value obtained from two-sample t-test; C, P-value obtained from Wilcoxon’s rank sum test